Finland’s Faron heads for London

18 Nov, 2015

Finnish biopharma company Faron Pharmaceuticals Oy has announced its successful £10 million placing and admission to trading on the AIM market of the London Stock Exchange.

Faron is a drug discovery and development company that currently has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy and vascular damage.

The company’s lead candidate is FP-1201-lyo (branded Traumakine®), a patent protected use of interferon beta which has been developed to treat acute respiratory distress syndrome (ARDS). The company has appointed a CRO in respect to the pan-European Phase III trial with first treatment expected to occur during Q4 of 2015.

Leading national audit, tax and advisory firm Crowe Clark Whitehill acted as reporting accountants to the transaction, with our capital markets team led by Stephen Bullock.

We were very pleased with the team at Crowe Clark Whitehill and would highly recommend them to other biopharmaceutical companies seeking admission to London’s capital markets.
— Yrjö Wichmann, CFO, Faron
We are excited to have supported Faron to list on the London market and strengthen its lead programme into a phase III study.
— Stephen Bullock, Corporate Finance Partner, Crowe Clark Whitehill
Follow my company on LinkedInFollow me on TwitterWatch my channel on YouTube